Experienced in Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency

Bella Bielorai

Tel Aviv, TA, IL 
Experienced in Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Bella Bielorai practices in Tel Aviv, Israel. Ms. Bielorai is rated as an Experienced expert by MediFind in the treatment of Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Kearns-Sayre Syndrome, Infantile Neutropenia, Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency.

Gender
Female

Locations

Tel Aviv, TA, Israel
Other Locations
Tel Litwinsky, TA, Israel
Ramat Gan, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3

46 Total Publications

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.
Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.
Journal: Antimicrobial agents and chemotherapy
Published: August 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bielorai's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile